Cytomegalovirus (HHV-5) Infections Pipeline Review Market Growth & Analysis Report 2015 Radiant Insights, Inc
Summary Radiant Insights's, 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015', provides an overview of the Cytomegalovirus (HHV-5) Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. Read Complete Report with TOC @ http://www.radiantinsights.com/research/cytomegalovirus-hhv-5-infections-pipeline-review-h2-2015 Radiant Insights's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Radiant Insights's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Radiant Insights's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Summary
Radiant Insights's, 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015', provides an overview of the Cytomegalovirus (HHV-5) Infections's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects.
Read Complete Report with TOC @ http://www.radiantinsights.com/research/cytomegalovirus-hhv-5-infections-pipeline-review-h2-2015
Radiant Insights's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Radiant Insights's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Radiant Insights's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> <strong>Pipeline</strong> <strong>Review</strong> <strong>Market</strong><br />
<strong>Growth</strong> & <strong>Analysis</strong> <strong>Report</strong> <strong>2015</strong>: <strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />
Summary<br />
<strong>Radiant</strong> <strong>Insights</strong>'s, '<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> <strong>Review</strong>, H2 <strong>2015</strong>', provides an<br />
overview of the <strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong>'s therapeutic pipeline.<br />
This report provides comprehensive information on the therapeutic development for <strong>Cytomegalovirus</strong><br />
(<strong>HHV</strong>-5) <strong>Infections</strong>, complete with comparative analysis at various stages, therapeutics assessment by<br />
drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with<br />
latest updates, and featured news and press releases. It also reviews key players involved in the<br />
therapeutic development for <strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> and special features on late-stage<br />
and discontinued projects.<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/cytomegalovirushhv-5-infections-pipeline-review-h2-<strong>2015</strong><br />
<strong>Radiant</strong> <strong>Insights</strong>'s report features investigational drugs from across globe covering over 20 therapy<br />
areas and nearly 3,000 indications. The report is built using data and information sourced from<br />
<strong>Radiant</strong> <strong>Insights</strong>'s proprietary databases, Company/University websites, SEC filings, investor<br />
presentations and featured press releases from company/university sites and industry-specific third<br />
party sources, put together by <strong>Radiant</strong> <strong>Insights</strong>'s team. Drug profiles/records featured in the report<br />
undergoes periodic updation following a stringent set of processes that ensures that all the profiles are<br />
updated with the latest set of information. Additionally, processes including live news & deals<br />
tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent<br />
developments are captured on a real time basis.<br />
The report enhances decision making capabilities and help to create effective counter strategies to<br />
gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to<br />
produce first-in-class and best-in-class products.<br />
Scope<br />
- The report provides a snapshot of the global therapeutic landscape of <strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5)<br />
<strong>Infections</strong><br />
- The report reviews key pipeline products under drug profile section which includes, product<br />
description, MoA and R&D brief, licensing and collaboration details & other developmental activities<br />
- The report reviews key players involved in the therapeutics development for <strong>Cytomegalovirus</strong><br />
(<strong>HHV</strong>-5) <strong>Infections</strong> and enlists all their major and minor projects<br />
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the <strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> products under development by companies<br />
and universities/research institutes based on information derived from company and industry-specific<br />
sources<br />
- <strong>Pipeline</strong> products coverage based on various stages of development ranging from pre-registration till<br />
discovery and undisclosed stages<br />
- A detailed assessment of monotherapy and combination therapy pipeline projects<br />
- Coverage of the <strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> pipeline on the basis of target, MoA, route of<br />
administration and molecule type<br />
- Latest news and deals relating related to pipeline products<br />
Reasons to buy<br />
- Provides strategically significant competitor information, analysis, and insights to formulate<br />
effective R&D development strategies<br />
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies<br />
to gain competitive advantage<br />
- Develop strategic initiatives by understanding the focus areas of leading companies<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/cytomegalovirushhv-5-infections-pipeline-review-h2-<strong>2015</strong><br />
- Identify and understand important and diverse types of therapeutics under development for<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong><br />
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline<br />
- Devise corrective measures for pipeline projects by understanding <strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5)<br />
<strong>Infections</strong> pipeline depth and focus of Indication therapeutics<br />
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with<br />
the most attractive projects to enhance and expand business potential and Scope<br />
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors<br />
that drove them from pipeline<br />
Table of Contents<br />
Table of Contents 2<br />
List of Tables 6<br />
List of Figures 7
Introduction 8<br />
<strong>Radiant</strong> <strong>Insights</strong> <strong>Report</strong> Coverage 8<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> Overview 9<br />
Therapeutics Development 10<br />
<strong>Pipeline</strong> Products for <strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Overview 10<br />
<strong>Pipeline</strong> Products for <strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Comparative <strong>Analysis</strong> 11<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Therapeutics under Development by Companies 12<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Therapeutics under Investigation by Universities/Institutes 15<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> Products Glance 16<br />
Late Stage Products 16<br />
Clinical Stage Products 17<br />
Early Stage Products 18<br />
Unknown Stage Products 19<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Products under Development by Companies 20<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/cytomegalovirushhv-5-infections-pipeline-review-h2-<strong>2015</strong><br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Products under Investigation by Universities/Institutes 23<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Companies Involved in Therapeutics Development 24<br />
AIMM Therapeutics B.V. 24<br />
Altor BioScience Corporation 25<br />
Applied Immune Technologies Ltd 26<br />
Astellas Pharma <strong>Inc</strong>. 27<br />
Atara Biotherapeutics, <strong>Inc</strong>. 28<br />
Bionor Pharma ASA 29<br />
Biotest AG 30<br />
CAP-CMV GmbH 31<br />
Cell Medica Limited 32<br />
Chimerix, <strong>Inc</strong>. 33
China Biologic Products, <strong>Inc</strong>. 34<br />
CyTuVax B.V. 35<br />
GlaxoSmithKline Plc 36<br />
Hookipa Biotech AG 37<br />
Humabs BioMed SA 38<br />
iQur Limited 39<br />
Kadmon Corporation, LLC 40<br />
Lead Discovery Center GmbH 41<br />
Merck & Co., <strong>Inc</strong>. 42<br />
Microbiotix, <strong>Inc</strong>. 43<br />
Novartis AG 44<br />
Pfizer <strong>Inc</strong>. 45<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/cytomegalovirushhv-5-infections-pipeline-review-h2-<strong>2015</strong><br />
Phoenix Biotechnology, <strong>Inc</strong>. 46<br />
Savoy Pharmaceuticals, <strong>Inc</strong>. 47<br />
Trellis Bioscience, <strong>Inc</strong>. 48<br />
Vakzine Projekt Management GmbH 49<br />
VBI Vaccines <strong>Inc</strong>. 50<br />
Vical <strong>Inc</strong>orporated 51<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Therapeutics Assessment 52<br />
Assessment by Monotherapy Products 52<br />
Assessment by Combination Products 53<br />
Assessment by Target 54<br />
Assessment by Mechanism of Action 56<br />
Assessment by Route of Administration 58<br />
Assessment by Molecule Type 60<br />
Drug Profiles 62
AL-18 - Drug Profile 62<br />
Antibodies to Inhibit HLA-A2 for <strong>Cytomegalovirus</strong> <strong>Infections</strong> - Drug Profile 63<br />
Antibody for Human <strong>Cytomegalovirus</strong> Infection - Drug Profile 64<br />
Antiviral TCR-Ck - Drug Profile 65<br />
Antiviral TCR-Ig - Drug Profile 66<br />
ASP-0113 - Drug Profile 67<br />
brincidofovir - Drug Profile 69<br />
BT-084 - Drug Profile 72<br />
CAPCMV-001 - Drug Profile 73<br />
Cell Therapy 3 For CMV - Drug Profile 74<br />
Cell Therapy for CMV <strong>Infections</strong> - Drug Profile 75<br />
Cell Therapy for <strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Drug Profile 76<br />
Cell Therapy for <strong>Cytomegalovirus</strong> <strong>Infections</strong> - Drug Profile 77<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/cytomegalovirushhv-5-infections-pipeline-review-h2-<strong>2015</strong><br />
Cell Therapy for <strong>Cytomegalovirus</strong> <strong>Infections</strong> - Drug Profile 78<br />
Cell Therapy for <strong>Cytomegalovirus</strong> <strong>Infections</strong> and GBM - Drug Profile 79<br />
Cell Therapy for Infectious Disease - Drug Profile 80<br />
Cell Therapy for Infectious Diseases - Drug Profile 81<br />
Cell Therapy for Viral <strong>Infections</strong> Post-HSCT - Drug Profile 82<br />
Cell Therapy to Target PP65 for <strong>Cytomegalovirus</strong> <strong>Infections</strong> - Drug Profile 83<br />
Cell Therapy to Target PP65 for <strong>Cytomegalovirus</strong> <strong>Infections</strong> - Drug Profile 85<br />
Cellular Immunotherapy for Viral <strong>Infections</strong> - Drug Profile 86<br />
CMX-669 - Drug Profile 87<br />
CSJ-148 - Drug Profile 88<br />
CyMVectin - Drug Profile 89<br />
<strong>Cytomegalovirus</strong> (virus like particles) vaccine - Drug Profile 90<br />
<strong>Cytomegalovirus</strong> vaccine - Drug Profile 91
<strong>Cytomegalovirus</strong> vaccine - Drug Profile 92<br />
<strong>Cytomegalovirus</strong> vaccine - Drug Profile 93<br />
<strong>Cytomegalovirus</strong> vaccine - Drug Profile 94<br />
<strong>Cytomegalovirus</strong> vaccine 1 - Drug Profile 95<br />
<strong>Cytomegalovirus</strong> vaccine 2 - Drug Profile 97<br />
Cytovir-CMV - Drug Profile 98<br />
Dendritic Cell Therapyto Target CMV Antigen for <strong>Cytomegalovirus</strong> <strong>Infections</strong> - Drug Profile 100<br />
Drug for <strong>Cytomegalovirus</strong> - Drug Profile 101<br />
filociclovir - Drug Profile 102<br />
Gene Therapy for <strong>Cytomegalovirus</strong> <strong>Infections</strong> - Drug Profile 104<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/cytomegalovirushhv-5-infections-pipeline-review-h2-<strong>2015</strong><br />
HB-101 - Drug Profile 105<br />
LDC-4297 - Drug Profile 106<br />
letermovir - Drug Profile 107<br />
maribavir - Drug Profile 108<br />
MBX-2168 - Drug Profile 110<br />
Monoclonal Antibody for <strong>Cytomegalovirus</strong> <strong>Infections</strong> - Drug Profile 111<br />
Monoclonal Antibody for HCMV <strong>Infections</strong> - Drug Profile 112<br />
Peptides to Inhibit Heparan Sulfate for <strong>HHV</strong>-5 <strong>Infections</strong> - Drug Profile 113<br />
RBT-301 - Drug Profile 114<br />
Recombinant Peptide for Infectious Diseases - Drug Profile 115<br />
RKP-00156 - Drug Profile 116<br />
Small Molecule 1 for Human <strong>Cytomegalovirus</strong> Infection - Drug Profile 117<br />
Small Molecule 2 for Human <strong>Cytomegalovirus</strong> Infection - Drug Profile 118<br />
Small Molecule 3 for Human <strong>Cytomegalovirus</strong> Infection - Drug Profile 119<br />
Small Molecules for CMV <strong>Infections</strong> - Drug Profile 120<br />
Small Molecules for Viral <strong>Infections</strong> - Drug Profile 121
Small Molecules to Activate Sirtuin for Viral <strong>Infections</strong> - Drug Profile 122<br />
Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV <strong>Infections</strong> - Drug Profile 123<br />
Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious<br />
Diseases - Drug Profile 124<br />
Small Molecules to Inhibit Na+/K+ ATPase for Human <strong>Cytomegalovirus</strong> <strong>Infections</strong> - Drug Profile<br />
125<br />
TRL-345 - Drug Profile 126<br />
V-160 - Drug Profile 127<br />
Vacc-CMV - Drug Profile 128<br />
Vaccine for <strong>Cytomegalovirus</strong> Infection and Glioblastoma Multiforme - Drug Profile 129<br />
VBI-1501A - Drug Profile 130<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/cytomegalovirushhv-5-infections-pipeline-review-h2-<strong>2015</strong><br />
Viralym-C - Drug Profile 131<br />
Viroprev - Drug Profile 132<br />
VPM-2001 - Drug Profile 133<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Recent <strong>Pipeline</strong> Updates 134<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Dormant Projects 154<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Discontinued Products 158<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Product Development Milestones 159<br />
Featured News & Press Releases 159<br />
Appendix 168<br />
Methodology 168<br />
Coverage 168<br />
Secondary Research 168<br />
Primary Research 168<br />
Expert Panel Validation 168<br />
Contact Us 168<br />
Disclaimer 169
List of Tables<br />
Number of Products under Development for <strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong>, H2 <strong>2015</strong> 14<br />
Number of Products under Development for <strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Comparative<br />
<strong>Analysis</strong>, H2 <strong>2015</strong> 15<br />
Number of Products under Development by Companies, H2 <strong>2015</strong> 17<br />
Number of Products under Development by Companies, H2 <strong>2015</strong> (Contd..1) 18<br />
Number of Products under Investigation by Universities/Institutes, H2 <strong>2015</strong> 19<br />
Comparative <strong>Analysis</strong> by Late Stage Development, H2 <strong>2015</strong> 20<br />
Comparative <strong>Analysis</strong> by Clinical Stage Development, H2 <strong>2015</strong> 21<br />
Comparative <strong>Analysis</strong> by Early Stage Development, H2 <strong>2015</strong> 22<br />
Comparative <strong>Analysis</strong> by Unknown Stage Development, H2 <strong>2015</strong> 23<br />
Products under Development by Companies, H2 <strong>2015</strong> 24<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/cytomegalovirushhv-5-infections-pipeline-review-h2-<strong>2015</strong><br />
Products under Development by Companies, H2 <strong>2015</strong> (Contd..1) 25<br />
Products under Development by Companies, H2 <strong>2015</strong> (Contd..2) 26<br />
Products under Investigation by Universities/Institutes, H2 <strong>2015</strong> 27<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by AIMM Therapeutics B.V., H2 <strong>2015</strong> 28<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Altor BioScience Corporation, H2 <strong>2015</strong> 29<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Applied Immune Technologies Ltd, H2 <strong>2015</strong> 30<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Astellas Pharma <strong>Inc</strong>., H2 <strong>2015</strong> 31<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Atara Biotherapeutics, <strong>Inc</strong>., H2 <strong>2015</strong> 32<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Bionor Pharma ASA, H2 <strong>2015</strong> 33<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Biotest AG, H2 <strong>2015</strong> 34<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by CAP-CMV GmbH, H2 <strong>2015</strong> 35<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Cell Medica Limited, H2 <strong>2015</strong> 36<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Chimerix, <strong>Inc</strong>., H2 <strong>2015</strong> 37<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by China Biologic Products, <strong>Inc</strong>., H2 <strong>2015</strong> 38
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by CyTuVax B.V., H2 <strong>2015</strong> 39<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by GlaxoSmithKline Plc, H2 <strong>2015</strong> 40<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Hookipa Biotech AG, H2 <strong>2015</strong> 41<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Humabs BioMed SA, H2 <strong>2015</strong> 42<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by iQur Limited, H2 <strong>2015</strong> 43<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Kadmon Corporation, LLC, H2 <strong>2015</strong> 44<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Lead Discovery Center GmbH, H2 <strong>2015</strong> 45<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Merck & Co., <strong>Inc</strong>., H2 <strong>2015</strong> 46<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Microbiotix, <strong>Inc</strong>., H2 <strong>2015</strong> 47<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Novartis AG, H2 <strong>2015</strong> 48<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Pfizer <strong>Inc</strong>., H2 <strong>2015</strong> 49<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/cytomegalovirushhv-5-infections-pipeline-review-h2-<strong>2015</strong><br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Phoenix Biotechnology, <strong>Inc</strong>., H2 <strong>2015</strong> 50<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Savoy Pharmaceuticals, <strong>Inc</strong>., H2 <strong>2015</strong> 51<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Trellis Bioscience, <strong>Inc</strong>., H2 <strong>2015</strong> 52<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Vakzine Projekt Management GmbH, H2 <strong>2015</strong> 53<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by VBI Vaccines <strong>Inc</strong>., H2 <strong>2015</strong> 54<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - <strong>Pipeline</strong> by Vical <strong>Inc</strong>orporated, H2 <strong>2015</strong> 55<br />
Assessment by Monotherapy Products, H2 <strong>2015</strong> 56<br />
Assessment by Combination Products, H2 <strong>2015</strong> 57<br />
Number of Products by Stage and Target, H2 <strong>2015</strong> 59<br />
Number of Products by Stage and Mechanism of Action, H2 <strong>2015</strong> 61<br />
Number of Products by Stage and Route of Administration, H2 <strong>2015</strong> 63<br />
Number of Products by Stage and Molecule Type, H2 <strong>2015</strong> 65<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> Therapeutics - Recent <strong>Pipeline</strong> Updates, H2 <strong>2015</strong> 138<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Dormant Projects, H2 <strong>2015</strong> 158<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Dormant Projects (Contd..1), H2 <strong>2015</strong> 159
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Dormant Projects (Contd..2), H2 <strong>2015</strong> 160<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Dormant Projects (Contd..3), H2 <strong>2015</strong> 161<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Discontinued Products, H2 <strong>2015</strong> 162<br />
List of Figures<br />
Number of Products under Development for <strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong>, H2 <strong>2015</strong> 14<br />
Number of Products under Development for <strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Comparative<br />
<strong>Analysis</strong>, H2 <strong>2015</strong> 15<br />
Number of Products under Development by Companies, H2 <strong>2015</strong> 16<br />
Number of Products under Investigation by Universities/Institutes, H2 <strong>2015</strong> 19<br />
Comparative <strong>Analysis</strong> by Late Stage Development, H2 <strong>2015</strong> 20<br />
Comparative <strong>Analysis</strong> by Clinical Stage Development, H2 <strong>2015</strong> 21<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/cytomegalovirushhv-5-infections-pipeline-review-h2-<strong>2015</strong><br />
About <strong>Radiant</strong> <strong>Insights</strong><br />
<strong>Radiant</strong> <strong>Insights</strong> is a platform for companies looking to meet their market research and business<br />
intelligence requirements. We assist and facilitate organizations and individuals procure market<br />
research reports, helping them in the decision making process. We have a comprehensive collection of<br />
reports, covering over 40 key industries and a host of micro markets. In addition to over extensive<br />
database of reports, our experienced research coordinators also offer a host of ancillary services such<br />
as, research partnerships/ tie-ups and customized research solutions.<br />
For More Information, Visit <strong>Radiant</strong> <strong>Insights</strong><br />
Contact:<br />
Michelle Thoras<br />
Corporate Sales Specialist, USA<br />
<strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />
Phone: 1-415-349-0054<br />
Toll Free: 1-888-202-9519<br />
Email: sales@radiantinsights.com<br />
Blog URL: http://www.radiantinsightsinc.blogspot.com
Change language